stoxline Quote Chart Rank Option Currency Glossary
Geron Corporation (GERN)
2.09  0.1 (5.03%)    12-07 16:00
Open: 2
High: 2.11
Volume: 5,341,305
Pre. Close: 1.99
Low: 1.961
Market Cap: 1,135(M)
Technical analysis
2023-12-07 4:20:54 PM
Short term     
Mid term     
Targets 6-month :  2.46 1-year :  2.87
Resists First :  2.1 Second :  2.46
Pivot price 1.95
Supports First :  1.84 Second :  1.67
MAs MA(5) :  1.97 MA(20) :  1.92
MA(100) :  2.25 MA(250) :  2.58
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  69 D(3) :  59.7
RSI RSI(14): 59.3
52-week High :  3.83 Low :  1.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GERN ] has closed above the upper band by 12.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.11 - 2.12 2.12 - 2.13
Low: 1.94 - 1.95 1.95 - 1.96
Close: 2.07 - 2.09 2.09 - 2.1
Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Headline News

Mon, 04 Dec 2023
Geron shares rise after positive trial results of blood disorder candidate (NASDAQ:GERN) - Seeking Alpha

Mon, 04 Dec 2023
Should You Accumulate Geron Corp (GERN) Stock Monday Morning? - InvestorsObserver

Mon, 04 Dec 2023
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Im - Benzinga

Thu, 30 Nov 2023
Where Will Geron Corp (GERN) Stock Go Next After It Has Risen 0.51% in a Week? - InvestorsObserver

Thu, 16 Nov 2023
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Fri, 03 Nov 2023
Earnings call: Geron Corporation Eyes $3.5 Billion Opportunity in MDS and MF Treatment Market By -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 543 (M)
Held by Insiders 4.9613e+008 (%)
Held by Institutions 0.1 (%)
Shares Short 44,940 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.882e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -29 %
Return on Assets (ttm) 31.7 %
Return on Equity (ttm) -36.6 %
Qtrly Rev. Growth 317000 %
Gross Profit (p.s.) -54.64
Sales Per Share -106.91
EBITDA (p.s.) -1.14232e+008
Qtrly Earnings Growth -0.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -162 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -1.2
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 3.17
Stock Dividends
Dividend 0
Forward Dividend 4.448e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android